vigabatrin has been researched along with Epilepsy, Temporal Lobe in 24 studies
Epilepsy, Temporal Lobe: A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vigabatrin (VGB) is a new antiepileptic drug that increases the human brain gamma-aminobutyric acid (GABA) level by irreversibly inhibiting GABA transaminase." | 6.70 | Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. ( Boesiger, P; Duc, CO; Meier, D; Mueller, SG; Russ, W; Weber, B; Weber, OM; Wieser, HG, 2001) |
| "The effect of introducing vigabatrin into the management of 57 patients with severe epilepsy is reported." | 3.68 | Vigabatrin: a three year clinical analysis. ( Martin, PJ; Millac, PA, 1993) |
| "Vigabatrin (VGB) is a new antiepileptic drug that increases the human brain gamma-aminobutyric acid (GABA) level by irreversibly inhibiting GABA transaminase." | 2.70 | Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. ( Boesiger, P; Duc, CO; Meier, D; Mueller, SG; Russ, W; Weber, B; Weber, OM; Wieser, HG, 2001) |
| " Thirty-seven patients discontinued vigabatrin for the following reasons: benefit-to-risk evaluation, 8; seizure breakthrough, 6; adverse events, 6; seizure breakthrough and adverse events, 5; moved or lost, 4; no longer eligible for study, 2; non-drug-related death, 2; narcotic abuse, 1; and patient request, three." | 2.67 | Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: an update. ( Ben-Menachem, E; Browne, TR; Mattson, RH; McBride, RG; Penry, JK; Sherry, KM; Smith, DB; Treiman, DM; Wilder, BJ, 1991) |
| " This may be related to dosage and speed of introduction." | 2.39 | Psychotic and severe behavioural reactions with vigabatrin: a review. ( Ferrie, CD; Panayiotopoulos, CP; Robinson, RO, 1996) |
| "Vigabatrin has been shown to protect against hippocampal neuronal cell death in experimental models of epilepsy." | 1.29 | Treatment with antiepileptic drugs: possible neuroprotective effects. ( Pitkänen, A, 1996) |
| "A study was conducted to assess the impact of single dosing and different dosing intervals of vigabatrin [gamma vinyl GABA (GVG)] in 11 patients with drug-resistant complex partial seizures." | 1.28 | Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans. ( Ben-Menachem, E, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 9 (37.50) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Androsova, G | 1 |
| Krause, R | 1 |
| Borghei, M | 1 |
| Wassenaar, M | 1 |
| Auce, P | 1 |
| Avbersek, A | 1 |
| Becker, F | 1 |
| Berghuis, B | 1 |
| Campbell, E | 1 |
| Coppola, A | 1 |
| Francis, B | 1 |
| Wolking, S | 1 |
| Cavalleri, GL | 1 |
| Craig, J | 1 |
| Delanty, N | 1 |
| Koeleman, BPC | 1 |
| Kunz, WS | 1 |
| Lerche, H | 1 |
| Marson, AG | 1 |
| Sander, JW | 1 |
| Sills, GJ | 1 |
| Striano, P | 1 |
| Zara, F | 1 |
| Sisodiya, SM | 1 |
| Depondt, C | 1 |
| André, V | 2 |
| Dubé, C | 1 |
| François, J | 1 |
| Leroy, C | 1 |
| Rigoulot, MA | 1 |
| Roch, C | 1 |
| Namer, IJ | 1 |
| Nehlig, A | 2 |
| Martin, PJ | 1 |
| Millac, PA | 1 |
| Pitkänen, A | 3 |
| Ferrie, CD | 1 |
| Robinson, RO | 1 |
| Panayiotopoulos, CP | 2 |
| Davie, MB | 1 |
| Cook, MJ | 1 |
| Ng, C | 1 |
| Mecarelli, O | 1 |
| De Feo, MR | 1 |
| Del Priore, D | 1 |
| Arroyo, S | 1 |
| Rumiá, J | 1 |
| Martínez, I | 1 |
| Ribalta, T | 1 |
| Hardus, P | 3 |
| Verduin, WM | 3 |
| Postma, G | 3 |
| Stilma, JS | 3 |
| Berendschot, TT | 3 |
| van Veelen, CW | 3 |
| García, A | 1 |
| Gutiérrez, MA | 1 |
| Barrasa, J | 1 |
| Herranz, JL | 1 |
| Lamusuo, S | 1 |
| Jutila, L | 1 |
| Ylinen, A | 2 |
| Partanen, K | 1 |
| Kälviäinen, R | 1 |
| Ruottinen, HM | 1 |
| Oikonen, V | 1 |
| Någren, K | 1 |
| Lehikoinen, P | 1 |
| Vapalahti, M | 1 |
| Vainio, P | 1 |
| Rinne, JO | 1 |
| Musshoff, U | 1 |
| Köhling, R | 1 |
| Lücke, A | 1 |
| Speckmann, E | 1 |
| Tuxhorn, I | 1 |
| Wolf, P | 1 |
| Pauuek, HW | 1 |
| Oppel, F | 1 |
| Theodore, WH | 1 |
| Mueller, SG | 1 |
| Weber, OM | 1 |
| Duc, CO | 1 |
| Weber, B | 1 |
| Meier, D | 1 |
| Russ, W | 1 |
| Boesiger, P | 1 |
| Wieser, HG | 2 |
| Kamermans, M | 1 |
| Ferrandon, A | 1 |
| Marescaux, C | 1 |
| Browne, TR | 2 |
| Mattson, RH | 2 |
| Penry, JK | 2 |
| Smith, DB | 2 |
| Treiman, DM | 2 |
| Wilder, BJ | 2 |
| Ben-Menachem, E | 3 |
| McBride, RG | 1 |
| Sherry, KM | 2 |
| Agosti, R | 1 |
| Yasargil, G | 1 |
| Egli, M | 1 |
| Wiestler, OD | 1 |
| Riekkinen, PJ | 1 |
| Halonen, T | 1 |
| Lehtinen, M | 1 |
| Sivenius, J | 1 |
| Shin, C | 1 |
| Rigsbee, LC | 1 |
| McNamara, JO | 1 |
| Napoliello, MJ | 1 |
| Szabo, GK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Vigabatrin on Cerebral Blood Flow and Glucose Metabolism[NCT00001489] | 20 participants | Observational | 1994-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for vigabatrin and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
Psychotic and severe behavioural reactions with vigabatrin: a review.
Topics: Adult; Anticonvulsants; Child; Contraindications; Dose-Response Relationship, Drug; Epilepsy; Epilep | 1996 |
PET: cerebral blood flow and glucose metabolism--pathophysiology and drug effects.
Topics: Anticonvulsants; Cerebrovascular Circulation; Epilepsy, Temporal Lobe; Glucose; Humans; Metabolic Cl | 2000 |
4 trials available for vigabatrin and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
[11 C]Flumazenil binding in the medial temporal lobe in patients with temporal lobe epilepsy: correlation with hippocampal MR volumetry, T2 relaxometry, and neuropathology.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Epilepsy, Temporal Lobe; Female; Flumazenil; GA | 2000 |
Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics.
Topics: Adolescent; Adult; Anticonvulsants; Brain; Brain Chemistry; Carnosine; Creatine; Epilepsy; Epilepsy, | 2001 |
Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: an update.
Topics: Aminocaproates; Anticonvulsants; Epilepsy, Temporal Lobe; Humans; Longitudinal Studies; Vigabatrin | 1991 |
Effect of gamma-vinyl GABA treatment on cholinergic and aminergic neurotransmission and on cyclic nucleotides in human complex partial epilepsy--a CSF study.
Topics: Acetylcholinesterase; Adult; Aminocaproates; Anticonvulsants; Brain; Epilepsy, Temporal Lobe; Female | 1988 |
18 other studies available for vigabatrin and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Ataxia; Benzodiazepines; Carbamazepine; Clobazam; | 2017 |
Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model.
Topics: Animals; Animals, Newborn; Anticonvulsants; Autoradiography; Cell Count; Cerebral Cortex; Deoxygluco | 2007 |
Vigabatrin: a three year clinical analysis.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Cerebral Cortex; Dose-Response Relationship, Dru | 1993 |
Treatment with antiepileptic drugs: possible neuroprotective effects.
Topics: Animals; Anticonvulsants; Epilepsy, Temporal Lobe; gamma-Aminobutyric Acid; Hippocampus; Humans; Ner | 1996 |
Vigabatrin overdose.
Topics: Adult; Anticonvulsants; Combined Modality Therapy; Drug Overdose; Epilepsy, Temporal Lobe; Female; g | 1996 |
Vigabatrin versus carbamazepine and phenytoin in kainic acid-treated pubescent rats.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Enzyme Inhi | 1997 |
[Drug-resistant epilepsy].
Topics: Adult; Anticonvulsants; Brain Neoplasms; Calcinosis; Carbamazepine; Diagnosis, Differential; Drug Re | 1998 |
Importance of specifying the type of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Child; Contraindications; Diagnosis, Differential; Epilepsies, Parti | 1999 |
Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
Topics: Anticonvulsants; Cross-Sectional Studies; Drug Resistance; Epilepsy, Temporal Lobe; Female; Humans; | 2000 |
Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.
Topics: Anticonvulsants; Epilepsy, Temporal Lobe; Follow-Up Studies; Humans; Linear Models; Statistics, Nonp | 2000 |
Cryptogenic gelastic epilepsy of frontal lobe origin: a paediatric case report.
Topics: Anticonvulsants; Child, Preschool; Diagnosis, Differential; Electroencephalography; Epilepsy, Fronta | 2000 |
Vigabatrin reduces epileptiform activity in brain slices from pharmacoresistant epilepsy patients.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Drug Resistanc | 2000 |
The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss.
Topics: Adult; Anticonvulsants; Electrooculography; Electroretinography; Epilepsy, Temporal Lobe; Humans; Mi | 2001 |
Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Antimanic Agents; Electroencephalography; Epilepsy, Temporal Lobe; Glutama | 2001 |
Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles.
Topics: Adult; Aminocaproates; Anticonvulsants; Epilepsy, Temporal Lobe; Female; Hippocampus; Humans; Micros | 1990 |
Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans.
Topics: Adult; Amino Acids; Aminocaproates; Anticonvulsants; Cerebrospinal Fluid; Epilepsy, Temporal Lobe; F | 1989 |
Anti-seizure and anti-epileptogenic effect of gamma-vinyl gamma-aminobutyric acid in amygdaloid kindling.
Topics: Aminocaproates; Amygdala; Animals; Anticonvulsants; Electrophysiology; Epilepsy, Temporal Lobe; gamm | 1986 |
Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up.
Topics: Aminocaproates; Anticonvulsants; Drug Interactions; Epilepsy, Temporal Lobe; Follow-Up Studies; Huma | 1987 |